Evidence map›Paper›PMID 30665947›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2019

Long-Term, Targeted Delivery of GDNF from Encapsulated Cells Is Neuroprotective and Reduces Seizures in the Pilocarpine Model of Epilepsy.

Giovanna Paolone, Chiara Falcicchia, Francesca Lovisari, Merab Kokaia, William J Bell, Tracie Fradet, Mario Barbieri, Lars U Wahlberg, Dwaine F Emerich, Michele Simonato

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Epilepsy grand challenge 2025.Frontiers in neurology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Gene and Cell Therapy for Epilepsy: A Mini Review.Frontiers in molecular neuroscience · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Giovanna PaoloneDepartment of Medical Science, Section of Pharmacology, Neuroscience Center, University of Ferrara and National Institute of Neuroscience, 44121 Ferrara, Italy, giovanna.paolone@univr.it.
Chiara FalcicchiaDepartment of Medical Science, Section of Pharmacology, Neuroscience Center, University of Ferrara and National Institute of Neuroscience, 44121 Ferrara, Italy.
Francesca LovisariDepartment of Medical Science, Section of Pharmacology, Neuroscience Center, University of Ferrara and National Institute of Neuroscience, 44121 Ferrara, Italy.
Merab KokaiaEpilepsy Centre, Department of Clinical Sciences, Lund University Hospital, 221 00 Lund, Sweden.ORCID 0000-0001-7984-3921
William J BellGloriana Therapeutics, Inc. (formerly NsGene Inc.), Providence, Rhode Island 02905.
Tracie FradetGloriana Therapeutics, Inc. (formerly NsGene Inc.), Providence, Rhode Island 02905.
Mario BarbieriDepartment of Medical Science, Section of Pharmacology, Neuroscience Center, University of Ferrara and National Institute of Neuroscience, 44121 Ferrara, Italy.
Lars U WahlbergGloriana Therapeutics, Inc. (formerly NsGene Inc.), Providence, Rhode Island 02905.
Dwaine F EmerichGloriana Therapeutics, Inc. (formerly NsGene Inc.), Providence, Rhode Island 02905.
Michele SimonatoDepartment of Medical Science, Section of Pharmacology, Neuroscience Center, University of Ferrara and National Institute of Neuroscience, 44121 Ferrara, Italy.
Mirna Therapeutics (United States) · USUniversity of Ferrara · ITLund University · SEVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurotrophic factors are candidates for treating epilepsy, but their development has been hampered by difficulties in achieving stable and targeted delivery of efficacious concentrations within the desired brain region. We have developed an encapsulated cell technology that overcomes these obstacles by providing a targeted, continuous,

Indexed as

AnimalsCell EncapsulationCell LineDrug Delivery SystemsEpilepsyGlial Cell Line-Derived Neurotrophic FactorHumansMaleNeuroprotective AgentsPilocarpineRats, Sprague-DawleySeizuresGlial Cell Line-Derived Neurotrophic FactorNeuroprotective AgentsPilocarpinecell therapyepilepsy comorbidityGDNFneurodegenerationneuroprotectiontemporal lobe epilepsy

Identifiers

PMID30665947
PMCPMC6507083
OpenAlexW2910152620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.